Skip to main content
SpringerLink
Log in

Cancer immunotherapy

The dark side of PD-1 receptor inhibition

  • News & Views
  • Published:

From Nature

View current issue Submit your manuscript

Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves. See Letter p.121

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Dual roles for the PD-1 receptor protein.

Notes

  1. See all news & views

References

  1. Wartewig, T. et al. Nature 552, 121–125 (2017).

    Article  ADS  CAS  Google Scholar 

  2. Sharpe, A. H. & Pauken, K. E. Nature Rev. Immunol. http://doi.org/gb2z5d (2017).

  3. Navarro, M. N. & Cantrell, D. A. Nature Immunol. 15, 808–814 (2014).

    Article  CAS  Google Scholar 

  4. Wolchok, J. D. et al. N. Engl. J. Med. 377, 1345–1356 (2017).

    Article  CAS  Google Scholar 

  5. Borghaei, H. et al. N. Engl. J. Med. 373, 1627–1639 (2017).

    Article  Google Scholar 

  6. Hude, I., Sasse, S., Engert, A. & Bröckelmann, P. J. Haematologica 102, 30–42 (2017).

    Article  CAS  Google Scholar 

  7. Wei, S. C. et al. Cell 170, 1120–1133 (2017).

    Article  CAS  Google Scholar 

  8. Gordon, S. R. et al. Nature 545, 495–499 (2017).

    Article  ADS  CAS  Google Scholar 

  9. Lesokhin, A. M. et al. J. Clin. Oncol. 34, 2698–2704 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, 02138, Massachusetts, USA

    Aya Ludin & Leonard I. Zon

  2. the Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts

    Leonard I. Zon

  3. the Howard Hughes Medical Institute, Boston

    Leonard I. Zon

Authors
  1. Aya Ludin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonard I. Zon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonard I. Zon.

Related links

Related links

Related links in Nature Research

https://doi.org/10.1038/nature23093

https://doi.org/10.1038/nature17310

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ludin, A., Zon, L. The dark side of PD-1 receptor inhibition. Nature 552, 41–42 (2017). https://doi.org/10.1038/nature24759

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature24759

  • Springer Nature Limited

This article is cited by

Search

Navigation